Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04196738
Other study ID # 49RC19_0195
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 30, 2020
Est. completion date October 26, 2022

Study information

Verified date January 2024
Source University Hospital, Angers
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the COMIX-R study is to assess the short term physiological effects of 3 ventilation strategies for adult patients with ARDS admitted to intensive care unit


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date October 26, 2022
Est. primary completion date October 26, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years or older - Invasive mechanical ventilation on tracheal probe - Acute respiratory distress syndrome, as defined by Berlin conference consensus, during hospitalization in intensive care, - Recovery phase of acute respiratory distress syndrome: spontaneous ventilation representing from 20 to 30% of ventilation in APRV mode. - No severe acidosis (pH> 7.30) - Patient affiliated to or beneficiary of a health care plan - Express consent of the patient or his/her SDM Exclusion Criteria: - Pneumothorax - Contraindication to the insertion of a nasogastric tube with an esophageal balloon - Contraindication to the use of Electrical impedance tomography (pacemaker) - Pregnancy, lactating or parturient woman

Study Design


Related Conditions & MeSH terms


Intervention

Other:
ventilation strategy
Patients are ventilated in randomised order with three different ventilation strategies: volume assist control (constant flow), Dual Mode or Airway Pressure Released Ventilation

Locations

Country Name City State
France University hospital Angers

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Angers

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary change of PaO2 (mmHg) Arterial partial pressure of dioxygen Of note: As it is a physiological study, all the primary and secondary outcomes will be analyzed with the same importance. 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes
Secondary -Respiratory rate variability variability of rate (per minute) 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes
Secondary -expiratory and inspiratory transpulmonary pressure calculated with the esophageal pressure (cm H20) 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes
Secondary -ventilation distribution in the lungs Electrical impedance tomography (EIT) assess distribution of tidal volume and of end-expiratory lung volume (EELV) (delta Z, IU) 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes
Secondary -other arterial parameters of hematosis pH, PaO2, PaCo2 (mmHg) 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes
Secondary -Work of breathing (WOB) calculated with esophageal pressure (Kg/m) 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes
Secondary -Pressure time product (PTP) -Pressure time product (PTP) calculated with esophageal pressure (cmH2O.s.min-1) 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes
Secondary -P0.1 pressure measured during the first 100 ms after an occlusion (cm H20) 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes
Secondary -PEEPi intrinsic positive end-expiratory pressure (cm H20) 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes
Secondary MAP mean arterial pressure 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes
Secondary HR heart rate (beats per minute) 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes
Secondary -Respiratory comfort visual analogic scale 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes
Secondary -Patient-ventilator asynchronies numbers of asynchronies analyzed on screen 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes
Secondary -Tidal volume variability variability of Tidal volume (mL) 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes
See also
  Status Clinical Trial Phase
Completed NCT04435613 - Clinical and Physiological Assessment of a Nearly Ultra-protective Lung Ventilation Strategy: A Quasi-experimental Preliminary Study in ARDS Patients N/A
Enrolling by invitation NCT05020210 - Effect of Early Treatment With Sivelestat Sodium in ARDS Patients
Completed NCT04468971 - REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia Phase 1
Completed NCT04505592 - Tenecteplase in Patients With COVID-19 Phase 2
Completed NCT04493242 - Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS Phase 2
Withdrawn NCT04909879 - Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome Phase 2
Completed NCT02265198 - Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome N/A
Completed NCT01949272 - Optimization of PEEP for Alveolar Recruitment in ARDS N/A
Not yet recruiting NCT01668368 - Goal Directed Mechanical Ventilation Aimed at Optimal Lung Compliance N/A
Completed NCT01881061 - Lung Sonography in Patients With Acute Respiratory Distress Syndrome in Intensive Care Unit N/A
Completed NCT00808691 - Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit N/A
Completed NCT05035589 - The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
Recruiting NCT04764032 - Right Ventricular Dysfunction in Ventilated Patients With COVID-19
Completed NCT04556513 - Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status
Recruiting NCT06036056 - NMR Based Metabolomics Kinetics in ARDS Patients
Recruiting NCT04503876 - Effects of End-expiratory Positive Pressure Optimization in Intubated Patients With Healthy Lung or Acute Respiratory Distress Syndrome N/A
Recruiting NCT04643691 - Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS Phase 2
Completed NCT04395911 - Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections N/A
Not yet recruiting NCT05341687 - Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in COVID-19 ARDS.
Recruiting NCT05056090 - Effect of Prone Positioning on Mortality in Patients With Mild to Moderate Acute Respiratory Distress Syndrome. N/A